Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | ASPH | Q12797 | 2/20 | 0.36 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16995132 | 0.82 | LMNA (0.36) | SMN1; SMN2LMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL12563900 | 0.79 | LMNA (0.34) | SMN1; SMN2LMNAALDH1A1NPC1RAB9A | |
| SCHEMBL28280472 | 0.79 | KDM4E (0.38) | SMN1; SMN2LMNAKDM4EALDH1A1ASPH | |
| SCHEMBL31713567 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNADPP4KDM4EALDH1A1 | |
| SCHEMBL392396 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNADPP4KDM4EALDH1A1 | |
| SCHEMBL1585518 | 0.78 | ATR (0.43) | LMNAKDM4EALDH1A1MAPK1KDM4C | |
| SCHEMBL9704180 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNADPP4KDM4EALDH1A1 | |
| SCHEMBL197777 | 0.78 | KDM4E (0.37) | SMN1; SMN2LMNADPP4KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9355662 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNADPP4KDM4EALDH1A1 | |
| SCHEMBL1245016 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNADPP4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| EP-4405344-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | Xenon Pharmaceuticals Inc. (CA) | 2024-07-31 | — | — | EP | disclosed |
| CN-118251389-A | Pyridyl derivatives as sodium channel activators | 泽农医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| WO-2023049369-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-03-30 | — | — | WO | disclosed |
| EP-1937682-A1 | MET KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1489083-B1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | KYORIN SEIYAKU KK (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-7030107-B2 | nitrogen compounds such as 5-[3,5-bis(trifluoromethyl)benzyl]-6-oxo-7-phenyl-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine, used as neurokinin inhibitors for prophylaxis of urogenital disorders; side effect reduction | KYORIN PHARMACEUTICAL.CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7026309-B2 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20050107375-A1 | Fused bicyclic pyridine derivatives as tachykinin receptor antagonists | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1489083-A1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1457493-A1 | FUSED BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | SMN1; SMN2 564/4885LMNA 287/4885DPP4 3190/4885 |
| US-20050107375-A1 | Fused bicyclic pyridine derivatives as tachykinin receptor antagonists | BDKRB1, BDKRB2, TACR1 | SMN1; SMN2 4623/4885LMNA 4430/4885DPP4 2127/4885 |
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | SMN1; SMN2 4254/4885LMNA 4721/4885DPP4 1791/4885 |
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | BDKRB1, BDKRB2, NPY1R | SMN1; SMN2 4769/4885LMNA 3941/4885DPP4 2771/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | SMN1; SMN2 4213/4885LMNA 4615/4885DPP4 4399/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | SMN1; SMN2 564/4885LMNA 287/4885DPP4 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.